Overview

Also Known As: Bim KO

These Bcl2l11^tm1.1Ast knock-out mice exhibit progressive systemic autoimmune disease. They may be useful in studies of apoptosis, degenerative and autoimmune diseases, including lupus erythematosus and autoimmune kidney disease.

Donating Investigator

Andreas Strasser, Walter and Eliza Hall Inst of Med Res

Genetic overview

Genetic Background	Generation
	N15+F7 (2019-07-11 00:00:00)

Bcl2l11^tm1.1Ast

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Bcl2l11	BCL2-like 11 (apoptosis facilitator)

View Genetics

Research Applications

Cancer Research
Immunology, Inflammation and Autoimmunity Research
Internal/Organ Research
Apoptosis Research

View All Research Applications

Base Price

Starting at:

$278.00 Domestic price for female

556.00 Domestic price for breeder pair

View Price List

Details

Detailed Description

Mice that are homozygous for the targeted mutation are viable, normal in size and do not display any gross physical or behavioral abnormalities. No full length gene product (protein) is immunodetected in spleen cells from homozygous mutant mice. Homozygous mice have lympho-myeloid hyperplasia and reduced platelet number. Lymphocytes are insensitive to certain apoptotic stimuli. Both homozygous and heterozygous mice exhibit progressive systemic autoimmune disease. This mutant mouse strain may be useful in studies of apoptosis, degenerative and autoimmune diseases, including lupus erythematosus and autoimmune kidney disease.

Development

A targeting vector containing a floxed neomycin resistance gene and a thymidine kinase gene was used to disrupt the exon encoding the BH3 domain. The construct was electroporated into 129S1 derived W9.5 embryonic stem (ES) cells. correctly targeted ES cells were injected into C57BL/6 blastocysts.

Control Suggestions

000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Bouillet P; Metcalf D; Huang DC; Tarlinton DM; Kay TW; Kontgen F; Adams JM; Strasser A. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286(5445):1735-8PubMed: 10576740 MGI: J:58641

View All References

Genetics

Bcl2l11^tm1.1Ast

Allele Symbol: Bcl2l11^tm1.1Ast

Allele Name	targeted mutation 1.1, Andreas Strasser
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	targeted mutation 1.1, Andreas Strasser; Bcl2l11^tm1.1Ast
Gene Symbol and Name	Bcl2l11, BCL2-like 11 (apoptosis facilitator)
Gene Synonym(s)	BOD; BIM; BimL; BAM; Bcl2 interacting mediator of cell death; RIKEN cDNA 1500006F24 gene; 1500006F24Rik; 1500006F24Rik; Bim; Bod; Bim
Strain of Origin	129S1/Sv-Oca2⁺ Tyr⁺ Kitl⁺
Chromosome	2
Molecular Note	Insertion of a floxed PGK-neomycin cassette deleted the exon encoding the BH3 domain. Cre-mediated recombination in vivo subsequently removed the inserted cassette. In the final allele a single loxP site remains in place of the exon. Immunoblot analysis using a rat monoclonal antibody did not detect full-length protein, but did detect a small amount of a truncated polypeptide in spleen cells from homozygous mutant mice.
Mutations Made By	Andreas Strasser, Walter and Eliza Hall Inst of Med Res

Disease/Phenotype

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Bcl2l11^tm1.1Ast related

Cancer Research
- Genes Regulating Growth and Proliferation
Immunology, Inflammation and Autoimmunity Research
- Intracellular Signaling Molecules
- Autoimmunity
Internal/Organ Research
- Spleen Defects
- Kidney Defects
  - polycystic kidney disease
Apoptosis Research
- Endogenous Regulators

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
involves: 129S1/Sv * C57BL/6

cardiovascular system phenotype

vasculitis
- about 20% of terminally ill homozygotes show signs of vasculitis or cardiac infarction

cellular phenotype

abnormal B cell proliferation
- anti-CD40 B cell proliferation is increased 3- to 5- fold in the presence of IL-21, which does not occur in wild-type controls

decreased B cell apoptosis
- IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice

increased renal glomerulus apoptosis
- higher numbers of apoptotic cells are detected in glomeruli compared to wild-type

homeostasis/metabolism phenotype

increased blood urea nitrogen level

immune system phenotype

abnormal B cell proliferation
- anti-CD40 B cell proliferation is increased 3- to 5- fold in the presence of IL-21, which does not occur in wild-type controls

abnormal lymphocyte physiology
- pre-B cells are also resistant to cell death induced by cytokine withdrawal, ionomycin, taxol, and dexamethasone but display sensitivity to cell death similar to wild-type following gamma irradiation or exposure to PMA or Fas ligand
- pre-T cells are resistant to dexamethasone or gamma-irradiation induced cell death but not to phorbol 12-myristate 13-acetate (PMA) or Fas ligand induced cell death
- pre-T cells cultured without cytokines or with ionomycin or taxol survive 10 to 30 times better than wild-type cells

abnormal plasma cell morphology
- at 6 to 12 months of age the number of IgM and IgG is increased by about 4-fold and 30- to 200-fold, respectively

abnormal spleen morphology

abnormal splenic cell ratio
- T1:follicular B cell ratio is higher than wild-type

decreased B cell apoptosis
- IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice

decreased double-positive T cell number
- in adult mice, thymic pre-T cells are reduced by about 50% compared to wild-type; however in newborns thymocyte composition is similar to wild-type

enlarged spleen
- in older homozygotes spleen size is increased 5- to 10-fold

glomerulonephritis
- by 1 year of about 85% of terminally ill homozygotes have immune complex glomerulonephritis

increased anti-double stranded DNA antibody level
- anti-SsDNA IgM and IgG antibodies are increased compared to wild-type

increased anti-histone antibody level
- increased compared to wild-type

increased anti-nuclear antigen antibody level
- anti-nuclear antibodies are increased compared to wild-type

increased anti-single stranded DNA antibody level
- anti-ssDNA IgM and IgG antibodies are increased compared to wild-type

increased autoantibody level
- total anti-IgM antibody levels are increased compared to wild-type

increased B cell number
- 2- to 4-fold increase

increased CD4-positive, alpha beta T cell number
- 2- to 3-fold increase in the number of CD4+ T cells is seen in adult mice

increased CD8-positive, alpha-beta T cell number
- 2- to 3-fold increase in the number of CD8+ T cells is seen in adult mice

increased double-negative T cell number
- 2- to 3-fold increase is seen in adult mice

increased follicular B cell number
- higher in spleen relative to wild-type and Fas^lpr homozygotes

increased granulocyte number
- 2- to 4-fold increase

increased IgA level
- elevated about 3-fold at 6 to 12 months of age

increased IgG level
- elevated about 10-fold at 6 to 12 months of age

increased IgM level
- elevated about 3-fold at 6 to 12 months of age

increased immature B cell number
- plasmablast numbers in spleen are increased relative to wild-type

increased inflammatory response

increased leukocyte cell number
- blood, spleen, and lymph node leukocyte numbers are elevated several fold mostly as a result of increased B and T cell counts
- however, the number of red cells is normal and the number of hematopoietic progenitor cells in the bone marrow is similar to wild-type
- these cells are mostly small, noncycling cells suggesting an increase in cell survival rather than proliferation

increased marginal zone B cell number
- higher in spleen relative to wild-type and Fas^lpr homozygotes

increased monocyte cell number
- 2- to 4-fold increase

increased splenocyte number
- total number of CD19+ splenocytes is higher than wild-type
- total number of splenocytes is increased relative to wild-type

increased susceptibility to autoimmune disorder
- older homozygotes develop lymphadenopathy

increased T cell number
- 2- to 4-fold increase involving mostly mature T cells is seen in adult mice

increased transitional stage B cell number
- higher numbers of T1 and T2 B cells in spleen relative to wild-type

spleen hyperplasia
- seen in older homozygotes with plasma cells most severely affected

vasculitis
- about 20% of terminally ill homozygotes show signs of vasculitis or cardiac infarction

hematopoietic system phenotype

abnormal B cell proliferation
- anti-CD40 B cell proliferation is increased 3- to 5- fold in the presence of IL-21, which does not occur in wild-type controls

abnormal lymphocyte physiology
- pre-B cells are also resistant to cell death induced by cytokine withdrawal, ionomycin, taxol, and dexamethasone but display sensitivity to cell death similar to wild-type following gamma irradiation or exposure to PMA or Fas ligand
- pre-T cells are resistant to dexamethasone or gamma-irradiation induced cell death but not to phorbol 12-myristate 13-acetate (PMA) or Fas ligand induced cell death
- pre-T cells cultured without cytokines or with ionomycin or taxol survive 10 to 30 times better than wild-type cells

abnormal plasma cell morphology
- at 6 to 12 months of age the number of IgM and IgG is increased by about 4-fold and 30- to 200-fold, respectively

abnormal spleen morphology

abnormal splenic cell ratio
- T1:follicular B cell ratio is higher than wild-type

decreased B cell apoptosis
- IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice

decreased double-positive T cell number
- in adult mice, thymic pre-T cells are reduced by about 50% compared to wild-type; however in newborns thymocyte composition is similar to wild-type

enlarged spleen
- in older homozygotes spleen size is increased 5- to 10-fold

increased B cell number
- 2- to 4-fold increase

increased CD4-positive, alpha beta T cell number
- 2- to 3-fold increase in the number of CD4+ T cells is seen in adult mice

increased CD8-positive, alpha-beta T cell number
- 2- to 3-fold increase in the number of CD8+ T cells is seen in adult mice

increased double-negative T cell number
- 2- to 3-fold increase is seen in adult mice

increased follicular B cell number
- higher in spleen relative to wild-type and Fas^lpr homozygotes

increased granulocyte number
- 2- to 4-fold increase

increased IgA level
- elevated about 3-fold at 6 to 12 months of age

increased IgG level
- elevated about 10-fold at 6 to 12 months of age

increased IgM level
- elevated about 3-fold at 6 to 12 months of age

increased immature B cell number
- plasmablast numbers in spleen are increased relative to wild-type

increased leukocyte cell number
- blood, spleen, and lymph node leukocyte numbers are elevated several fold mostly as a result of increased B and T cell counts
- however, the number of red cells is normal and the number of hematopoietic progenitor cells in the bone marrow is similar to wild-type
- these cells are mostly small, noncycling cells suggesting an increase in cell survival rather than proliferation

increased marginal zone B cell number
- higher in spleen relative to wild-type and Fas^lpr homozygotes

increased monocyte cell number
- 2- to 4-fold increase

increased splenocyte number
- total number of CD19+ splenocytes is higher than wild-type
- total number of splenocytes is increased relative to wild-type

increased T cell number
- 2- to 4-fold increase involving mostly mature T cells is seen in adult mice

increased transitional stage B cell number
- higher numbers of T1 and T2 B cells in spleen relative to wild-type

spleen hyperplasia
- seen in older homozygotes with plasma cells most severely affected

thrombocytopenia
- platelet count is reduced to about 1/2 of wild-type; however, megakaryocyte numbers are normal

mammalian phenotype

nervous system phenotype
- Normal - unlike mice homozygous for Bbc3^tm1Ast neuron sensitivity to oxidative stressor induced apoptosis is similar to controls

mortality/aging

embryonic lethality during organogenesis, incomplete penetrance
- Background Sensitivity - about half die before E10; however, this percentage is highly variable and background dependent

premature death
- by 1 year of age 55% of homozygotes are terminally ill with 85% of these developing kidney disease (immune complex glomerulonephritis)

renal/urinary system phenotype

abnormal kidney morphology
- number of macrophages surrounding glomeruli is increased compared to wild-type and Fas^lpr homozygotes
- number of macrophages surrounding glomeruli is increased compared to wild-type, and is similar to that in double mutants

abnormal renal glomerulus basement membrane morphology
- IgG deposits mainly localized to glomerular basement membrane are increased relative to wild-type

abnormal renal glomerulus morphology
- hypercellularity is seen in homozygotes with kidney disease

dilated renal tubules
- eosinophilic deposits are seen in dilated renal tubules in homozygotes with kidney disease

expanded mesangial matrix

glomerular crescent
- proliferation of capsular epithelial cells is seen in homozygotes with kidney disease

glomerulonephritis
- by 1 year of about 85% of terminally ill homozygotes have immune complex glomerulonephritis

increased renal glomerulus apoptosis
- higher numbers of apoptotic cells are detected in glomeruli compared to wild-type

renal cast
- dilated renal tubules contain eosinophilic casts

renal glomerular immunoglobulin deposits

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11⁺
involves: 129S1/Sv * C57BL/6

cardiovascular system phenotype

vasculitis
- about 20% of terminally ill heterozygotes show signs of vasculitis or cardiac infarction

mortality/aging

premature death
- by 1 year of age 35% of heterozygotes are terminally ill

renal/urinary system phenotype

glomerulonephritis
- by 1 year of about 85% of terminally ill heterozygotes have immune complex glomerulonephritis

renal glomerular immunoglobulin deposits

hematopoietic system phenotype

abnormal lymphocyte physiology
- pre-T cells cultured without cytokines or with ionomycin or taxol survive better than wild-type cells but not as well as homozygous cells

increased IgA level
- increased at 6 to 12 months of age but less than in homozygous mice

increased IgG level
- increased at 6 to 12 months of age but less than in homozygous mice

increased IgM level
- increased at 6 to 12 months of age but less than in homozygous mice

immune system phenotype

abnormal lymphocyte physiology
- pre-T cells cultured without cytokines or with ionomycin or taxol survive better than wild-type cells but not as well as homozygous cells

glomerulonephritis
- by 1 year of about 85% of terminally ill heterozygotes have immune complex glomerulonephritis

increased IgA level
- increased at 6 to 12 months of age but less than in homozygous mice

increased IgG level
- increased at 6 to 12 months of age but less than in homozygous mice

increased IgM level
- increased at 6 to 12 months of age but less than in homozygous mice

increased susceptibility to autoimmune disorder
- older heterozygotes develop lymphadenopathy

vasculitis
- about 20% of terminally ill heterozygotes show signs of vasculitis or cardiac infarction

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
involves: 129S1/Sv

cellular phenotype

decreased splenocyte apoptosis
- almost no loss of cellular viability ex vivo upon cytokine depletion compared with wild-type

decreased thymocyte apoptosis
- ex vivo upon cytokine depletion compared with wild-type
- in response to cis-diammine-dichloroplatinum II (cisplatin), phorbol 12- myristate 13-acetate (PMA), dexamethasone (Dex), anti-Fas, and UV irradiation

immune system phenotype

abnormal CD4-positive, alpha beta T cell number
- 2- to 4- fold increase

abnormal CD8-positive, alpha-beta T cell physiology
- HSV-1 antigen specific CD8+ T cells show nearly complete resistance to cytokine withdrawal induced apoptosis in culture

abnormal splenic cell ratio
- increase in the number of HSV-1 specific T cells in the spleen but not lymph nodes after infection

decreased splenocyte apoptosis
- almost no loss of cellular viability ex vivo upon cytokine depletion compared with wild-type

decreased thymocyte apoptosis
- ex vivo upon cytokine depletion compared with wild-type
- in response to cis-diammine-dichloroplatinum II (cisplatin), phorbol 12- myristate 13-acetate (PMA), dexamethasone (Dex), anti-Fas, and UV irradiation

increased B cell number
- 2- to 4- fold increase in B220+ positive cells

integument phenotype

abnormal involution of the mammary gland
- delay in postlactational remodeling of the mammary gland

mammalian phenotype

hematopoietic system phenotype
- Normal - unlike in Bnip3l^tm1Ney homozygotes, reticulocytes clearance of mitochondria is normal

endocrine/exocrine gland phenotype

abnormal involution of the mammary gland
- delay in postlactational remodeling of the mammary gland

decreased thymocyte apoptosis
- ex vivo upon cytokine depletion compared with wild-type
- in response to cis-diammine-dichloroplatinum II (cisplatin), phorbol 12- myristate 13-acetate (PMA), dexamethasone (Dex), anti-Fas, and UV irradiation

hematopoietic system phenotype

abnormal CD4-positive, alpha beta T cell number
- 2- to 4- fold increase

abnormal CD8-positive, alpha-beta T cell physiology
- HSV-1 antigen specific CD8+ T cells show nearly complete resistance to cytokine withdrawal induced apoptosis in culture

abnormal splenic cell ratio
- increase in the number of HSV-1 specific T cells in the spleen but not lymph nodes after infection

decreased splenocyte apoptosis
- almost no loss of cellular viability ex vivo upon cytokine depletion compared with wild-type

decreased thymocyte apoptosis
- ex vivo upon cytokine depletion compared with wild-type
- in response to cis-diammine-dichloroplatinum II (cisplatin), phorbol 12- myristate 13-acetate (PMA), dexamethasone (Dex), anti-Fas, and UV irradiation

increased B cell number
- 2- to 4- fold increase in B220+ positive cells

The following phenotype relates to a compound genotype created using this strain

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129S1-Bcl2l11

cellular phenotype

decreased apoptosis
- NK cells are more resistant to LY294002-induced apoptosis
- sympathetic neurons are partially protected from apoptosis induced by the withdrawal of nerve growth factor

decreased B cell apoptosis
- about 10-fold more B cells cultured without cytokines are alive after six days compared to controls

decreased T cell apoptosis
- about 10-fold more T cells cultured without cytokines are alive after six days compared to controls
- double positive T cells with increased resistance to the apoptotic effects of dexamethasone

homeostasis/metabolism phenotype

decreased physiological sensitivity to xenobiotic
- NK cells are more resistant to LY294002-induced apoptosis

immune system phenotype

abnormal B cell morphology

abnormal leukopoiesis
- irradiated mice reconstituted with mutant fetal liver cells have a 2- to 4- fold increase in lymphocyte and myeloid cell numbers compared to controls

abnormal lymphocyte physiology
- survival of mature resting T and B cells in the absence of cytokines is improved compared to wild-type cells

abnormal NK cell morphology
- following expansion in culture, NK cells survive IL-15 withdrawal better than wild-type cells

abnormal response to infection
- following infection with mouse cytomegalovirus infection, more NK cell survive at day 10 and 14 than in wild-type mice

decreased B cell apoptosis
- about 10-fold more B cells cultured without cytokines are alive after six days compared to controls

decreased T cell apoptosis
- about 10-fold more T cells cultured without cytokines are alive after six days compared to controls
- double positive T cells with increased resistance to the apoptotic effects of dexamethasone

increased immature B cell number

increased leukocyte cell number
- increased white blood cells numbers (>3 fold)

increased mature B cell number

increased NK cell number
- mice have a higher percent of KLRG1+CD27- NK cells in the spleen, liver and bone marrow compared to wild-type mice

increased regulatory T cell number
- at 6 months

increased spleen weight
- increased spleen weight (>2.5 fold)

increased transitional stage B cell number
- increased T1 transitional B cells in inguinal lymph nodes
- T1 transitional B cells are insignificantly elevated

mammalian phenotype

immune system phenotype
- Normal - normal in vitro survival assays with several cytotoxic stimuli on sorted thymocyte and B cell populations

nervous system phenotype

abnormal sympathetic neuron morphology
- sympathetic neurons are partially protected from apoptosis induced by the withdrawal of nerve growth factor

hematopoietic system phenotype

abnormal B cell morphology

abnormal leukopoiesis
- irradiated mice reconstituted with mutant fetal liver cells have a 2- to 4- fold increase in lymphocyte and myeloid cell numbers compared to controls

abnormal lymphocyte physiology
- survival of mature resting T and B cells in the absence of cytokines is improved compared to wild-type cells

abnormal NK cell morphology
- following expansion in culture, NK cells survive IL-15 withdrawal better than wild-type cells

decreased B cell apoptosis
- about 10-fold more B cells cultured without cytokines are alive after six days compared to controls

decreased T cell apoptosis
- about 10-fold more T cells cultured without cytokines are alive after six days compared to controls
- double positive T cells with increased resistance to the apoptotic effects of dexamethasone

increased immature B cell number

increased leukocyte cell number
- increased white blood cells numbers (>3 fold)

increased mature B cell number

increased NK cell number
- mice have a higher percent of KLRG1+CD27- NK cells in the spleen, liver and bone marrow compared to wild-type mice

increased regulatory T cell number
- at 6 months

increased spleen weight
- increased spleen weight (>2.5 fold)

increased transitional stage B cell number
- increased T1 transitional B cells in inguinal lymph nodes
- T1 transitional B cells are insignificantly elevated

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129-Bcl2l11/J

hematopoietic system phenotype

decreased lymphocyte cell number

immune system phenotype

decreased lymphocyte cell number

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11⁺
B6.129S1-Bcl2l11

hematopoietic system phenotype

increased leukocyte cell number
- increased white blood cells numbers (<1.5 fold)

increased spleen weight
- increase in spleen weight (<2 fold)

immune system phenotype

increased leukocyte cell number
- increased white blood cells numbers (<1.5 fold)

increased spleen weight
- increase in spleen weight (<2 fold)

mammalian phenotype

immune system phenotype
- Normal - normal in vitro survival assays with several cytotoxic stimuli on sorted thymocyte and B cell populations

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129S1-Bcl2l11/J

cellular phenotype

decreased T cell apoptosis
- increased viability of CD4 and CD8 T cells during in vitro culture of T cells purified from spleen and lymph nodes

hematopoietic system phenotype

decreased T cell apoptosis
- increased viability of CD4 and CD8 T cells during in vitro culture of T cells purified from spleen and lymph nodes

increased B cell number
- a large increase in the number of B cells in the spleen

increased CD4-positive, alpha beta T cell number
- a large increase in the number of CD4-positive T cells in the spleen

increased CD8-positive, alpha-beta T cell number
- a large increase in the number of CD8-positive T cells in the spleen

increased splenocyte number
- increased number of splenocytes (>3 fold)

immune system phenotype

decreased T cell apoptosis
- increased viability of CD4 and CD8 T cells during in vitro culture of T cells purified from spleen and lymph nodes

increased B cell number
- a large increase in the number of B cells in the spleen

increased CD4-positive, alpha beta T cell number
- a large increase in the number of CD4-positive T cells in the spleen

increased CD8-positive, alpha-beta T cell number
- a large increase in the number of CD8-positive T cells in the spleen

increased splenocyte number
- increased number of splenocytes (>3 fold)

References

Bouillet P; Metcalf D; Huang DC; Tarlinton DM; Kay TW; Kontgen F; Adams JM; Strasser A. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286(5445):1735-8PubMed: 10576740 MGI: J:58641

Additional References

Bouillet P; Zhang LC; Huang DC; Webb GC; Bottema CD; Shore P; Eyre HJ; Sutherland GR; Adams JM. 2001. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 12(2):163-8PubMed: 11210187 MGI: J:69112
Bouillet P; Purton JF; Godfrey DI; Zhang LC; Coultas L; Puthalakath H; Pellegrini M; Cory S; Adams JM; Strasser A. 2002. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415(6874):922-6PubMed: 11859372 MGI: J:74991
Akiyama T; Bouillet P; Miyazaki T; Kadono Y; Chikuda H; Chung UI; Fukuda A; Hikita A; Seto H; Okada T; Inaba T; Sanjay A; Baron R; Kawaguchi H; Oda H; Nakamura K; Strasser A; Tanaka S. 2003. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 22(24):6653-6664PubMed: 14657036 MGI: J:87072

Additional - Bcl2l11^tm1.1Ast related

Technical Support

Contact Technical Support

Genotyping Protocols
- Probe: Bcl2l11^tm1.1Ast -Probe Alternate2
- Separated PCR: Bcl2l11^tm1.1Ast-Alternate 1
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

The resulting chimeric animals were crossed to a C57BL/6 Cre-deleter strain to remove the neo cassette, and then backcrossed to C57BL/6 for 13 generations. Donating Investigator reports that homozygous females, although fertile, tend to be poor mothers; uses the following breeding scheme: heterozygous females X homozygous males . 5-7 pups per litter.
- Additional Breeding and Husbandry Support
Mating System
- Heterozygote x Homozygote
Citation
When using the Bim KO mouse strain in a publication, please cite the originating article(s) and include JAX stock #004525 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX11 (Maximum)

Pricing & Availability

Available

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Breeder Pair

Sex

Genotype

Price

Female
Male

Cryorecovery - Pricing

Service	Genotype	Price
	Heterozygous for Bcl2l11<tm1.1Ast>

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Related Products and Services

Frozen Mouse Embryo

$2,595.00 per straw or vial

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: Bim KO

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Bcl2l11tm1.1Ast

Allele Symbol: Bcl2l11tm1.1Ast

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Bcl2l11tm1.1Ast related

Mammalian Phenotype Terms by Genotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11tm1.1Astinvolves: 129S1/Sv * C57BL/6

cardiovascular system phenotype

cellular phenotype

homeostasis/metabolism phenotype

immune system phenotype

hematopoietic system phenotype

mammalian phenotype

mortality/aging

renal/urinary system phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11+involves: 129S1/Sv * C57BL/6

cardiovascular system phenotype

mortality/aging

renal/urinary system phenotype

hematopoietic system phenotype

immune system phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11tm1.1Astinvolves: 129S1/Sv

cellular phenotype

immune system phenotype

integument phenotype

mammalian phenotype

endocrine/exocrine gland phenotype

hematopoietic system phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11tm1.1AstB6.129S1-Bcl2l11

cellular phenotype

homeostasis/metabolism phenotype

immune system phenotype

mammalian phenotype

nervous system phenotype

hematopoietic system phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11tm1.1AstB6.129-Bcl2l11/J

hematopoietic system phenotype

immune system phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11+B6.129S1-Bcl2l11

hematopoietic system phenotype

immune system phenotype

mammalian phenotype

Genotype: Bcl2l11tm1.1Ast/Bcl2l11tm1.1AstB6.129S1-Bcl2l11/J

cellular phenotype

hematopoietic system phenotype

immune system phenotype

References

Additional References

Additional - Bcl2l11tm1.1Ast related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Citation

Animal Health Reports

Live Mouse

Breeder Pair

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Bcl2l11^tm1.1Ast

Allele Symbol: Bcl2l11^tm1.1Ast

Genotype: Bcl2l11^tm1.1Ast related

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
involves: 129S1/Sv * C57BL/6

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11⁺
involves: 129S1/Sv * C57BL/6

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
involves: 129S1/Sv

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129S1-Bcl2l11

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129-Bcl2l11/J

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11⁺
B6.129S1-Bcl2l11

Genotype: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast
B6.129S1-Bcl2l11/J

Additional - Bcl2l11^tm1.1Ast related